Skip to main content
Menu
US

HTRF Human Total Estrogen Receptor α Detection Kit, 500 Assay Points

The Human Estrogen Receptor alpha kit is designed to monitor the expression level of cellular Estrogen Receptor alpha.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Protein Quantification
Sample Volume 16 µL

The Human Estrogen Receptor alpha kit is designed to monitor the expression level of cellular Estrogen Receptor alpha.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 500 Assay Points
Part #:
64ERAPEG
List Price
USD 2,147.00
Unit Size: 10,000 Assay Points
Part #:
64ERAPEH
List Price
USD 12,490.00

Overview

The HTRF Human Estrogen Receptor Alpha detection assay monitors the expression of endogenous or overexpressed Estrogen Receptor Alpha in various cells.

Estrogen Receptor Alpha is a type of nuclear receptor that is activated by estrogen hormones, like Estradiol (E2).

Estrogens bind to the ligand binding domain of the Estrogen Receptor Alpha, resulting in receptor homodimerization and translocation to the nucleus. This activates downstream gene expression and the activation of signaling pathways, like the PI3K/AKT pathway. The gene expression induced by Estrogen Receptor Alpha results in cell division and proliferation. A dysregulation of the Estrogen Receptor Alpha pathway could lead to oncogenic phenotypes, and Estrogen Receptor Alpha activation or overexpression has been widely linked to breast cancer (in more than 70% of the cases). Estrogen Receptor Alpha has therefore become an important drug target for the pharmaceutical industry. The development of PROTAC compounds to target Estrogen Receptor Alpha degradation is a part of the therapeutic strategy to target Estrogen Receptor Alpha positive cancers. Alternatively Selective Estrogen Receptor Degrader (SERD) can be detected with this kit, but not Selective Estrogen Receptor Modulator (SERM) as they only impact downstream signaling and not the expression level of the protein.

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
HTRF
Detection Modality
HTRF
Lysis Buffer Compatibility
Lysis Buffer 1
Lysis Buffer 2
Lysis Buffer 3
Lysis Buffer 4
Product Group
Kit
Sample Volume
16 µL
Shipping Conditions
Shipped in Dry Ice
Target Class
Biomarkers
Target Species
Human
Technology
TR-FRET
Therapeutic Area
Oncology & Inflammation
Unit Size
500 Assay Points

Video gallery

How it works

Human Total Estrogen Receptor alpha Detection Kit assay principle

The HTRF Human Estrogen Receptor-alpha assay quantifies the expression level of Estrogen Receptor-alpha in a cell lysate. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Human Estrogen Receptor-alpha assay uses two labeled antibodies: one coupled to a donor fluorophore, the other to an acceptor. Both antibodies are highly specific for a distinct epitope on the protein. In presence of Estrogen Receptor-alpha in a cell extract, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the protein present in the sample, and provides a means of assessing the protein's expression under a no-wash assay format

human-total-estrogen-receptor-alpha-detection-kit

 

Human Total Estrogen Receptor alpha Detection Kit two -plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a 384-well low volume detection plate before the addition of Human Estrogen Receptor-alpha HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

human-total-estrogen-receptor-alpha-detection-kit

 

Human Total Estrogen Receptor alpha Detection Kit one-plate assay protocol

Detection of Human Estrogen Receptor-alpha with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

human-total-estrogen-receptor-alpha-detection-kit

 

Assay validation

Screning of compound on breast cancer cells

The human breast cancer cell line MCF7 or T47D were seeded in a 96-well culture-treated plate under 25,000 cells / well or 50,000 cell / well respectively in complete culture medium, and incubated overnight at 37 ° C, 5% CO2. The cells were treated with Tamoxifen (SERM), Fulvestran (SERD) or ARV-471 (PROTAC) compound for 4h. After treatment, the cells were lyzed with 50 µL of supplemented lysis buffer # 4 for 30 minutes at RT under gentle shaking. For the detection step, 16 µL of cell lysate were transferred into a 384-well low volume white microplate, and 4 µL of the HTRF Human Estrogen Receptor Alpha detection reagents were added. The HTRF signal was recorded after an overnight of incubation.

As expected, Fulvestran and ARV-471 induce a dose-dependent decrease of Estrogen receptor alpha expression, while Tamoxifen have no effect.

human-total-estrogen-receptor-alpha-detection-kit

 

human-total-estrogen-receptor-alpha-detection-kit

 

Validation of PROTAC effect

The human breast cancer cell line MCF7 were seeded in a 96-well culture-treated plate under 25,000 cells / well in complete culture medium, and incubated overnight at 37 ° C, 5% CO2. The cells were treated during 4h with ERD-308, a PROTAC compound based on VHL ligand 1 and Raloxifène. An irrelevant PROTAC, dBET6 (targeting BRD4 and Cereblon) was used to validate specificity. After treatment, the cells were lyzed with 50 µL of supplemented lysis buffer # 4 for 30 minutes at RT under gentle shaking. For the detection step, 16 µL of cell lysate were transferred into a 384-well low volume white microplate, and 4 µL of the HTRF Human Estrogen Receptor Alpha detection reagents were added. The HTRF signal was recorded after an overnight of incubation.

As expected, only the PROTAC composed of an Estrogen Receptor Alpha ligand and an E3 ligase ligand provoke the protein degradation, not the subunits or an irrelevant PROTAC. GAPDH, a housekeeping protein was used to monitor the cell viability and validate that only the targeted protein was degraded.

human-total-estrogen-receptor-alpha-detection-kit

 

human-total-estrogen-receptor-alpha-detection-kit

 

HTRF Human Estrogen Receptor alpha phrmacology compared to Western Blot

The human breast cancer cell line MCF7 were seeded in a 96-well culture-treated plate under 25,000 cells / well in complete culture medium, and incubated overnight at 37 ° C, 5% CO2. The cells were treated with the ARV-471 or ERD-308 PROTAC compound to a concentration range of 0.02 nM to 100 nM for 4h. After treatment, the cells were lyzed with 50 µL of supplemented lysis buffer # 4 for 30 minutes at RT under gentle shaking. For the detection step, 16 µL of cell lysate were transferred into a 384-well low volume white microplate, and 4 µL of the HTRF Human Estrogen Receptor Alpha detection reagents were added. The HTRF signal was recorded after an overnight of incubation.

A comparison between the HTRF Human Estrogen Receptor Alpha kit and the detection of the protein by western blot was done. The PROTAC compound induce the dose-dependent degradation of Estrogen Receptor Alpha with a IC50 of 1.3 nM for the ARV-471 and 3.7nM for ERD-308. The Estrogen Receptor Alpha degradation obtained with ERD-308 is stronger than with ARV-471 because there is less protein remaining at the maximum concentration of botch compounds.

human-total-estrogen-receptor-alpha-detection-kit

 

human-total-estrogen-receptor-alpha-detection-kit

 

HTRF Human Estrogen Receptor alpha sensitivity compared to Western Blot

The human breast cancer cell line MCF7 was cultured in a T175 flask in complete culture medium for 48h at 37 ° C, 5% CO2. The cells were lyzed with 3 mL of supplemented lysis buffer # 4 for 30 minutes at RT under gentle shaking.

Serial dilutions of the cell lysate were performed using supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF Human Estrogen Receptor Alpha detection reagents. Equal amounts of lysates were used for a side-by-side comparison between HTRF and Western Blot.

Using the HTRF Human Estrogen Receptor Alpha assay, 1,000 cells / well were enough to detect a significant signal, while 8,100 cells were needed to obtain a minimal chemiluminescent signal using Western Blot. Therefore, in these conditions, the HTRF Human Estrogen Receptor Alpha assay was 8 times more sensitive than the Western Blot technique.

human-total-estrogen-receptor-alpha-detection-kit

 

Simplified pathway

Estrogen Receptor alpha Signaling Pathway

Estrogen Receptor (ER) is a type of nuclear receptor that is activated by estrogen hormones, like Estradiol (E2). The estrogen hormones cross the cell membrane to bind directly onto the Estrogen Receptor, inducing homodimerization of the Estrogen Receptor and permitting nucleus translocation. The Estrogen Receptor dimers then bind to the Estrogen Response Element (ERE) to lead gene expression, resulting in cell division, proliferation, and differentiation.

human-total-estrogen-receptor-alpha-detection-kit

 

Resources

Are you looking for resources, click on the resource type to explore further.

1-2 of 2 Resources
Brochure Icon
Brochure
HTRF assays and reagents catalog

Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...

Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Scroll Icon